Icalcaprant

Icalcaprant
Clinical data
Other names	CVL-354
Routes of; administration	Oral administration
Drug class	Opioid antagonist; κ-Opioid receptor antagonist
Identifiers
	IUPAC name 4-[4-{{(2S)-2-(3-methoxy-1-methylpyrazol-4-yl)pyrrolidin-1-yl]methyl]phenoxy]benzamide;
CAS Number	2227384-17-8;
PubChem CID	134540598;
UNII	GNR4JZG668;
KEGG	D13002;
ChEMBL	ChEMBL5314519;
Chemical and physical data
Formula	C23H26N4O3
Molar mass	406.486 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C=C(C(=N1)OC)[C@@H]2CCCN2CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)N;
	InChI InChI=1S/C23H26N4O3/c1-26-15-20(23(25-26)29-2)21-4-3-13-27(21)14-16-5-9-18(10-6-16)30-19-11-7-17(8-12-19)22(24)28/h5-12,15,21H,3-4,13-14H2,1-2H3,(H2,24,28)/t21-/m0/s1; Key:OBDLEFCGVHQDFR-NRFANRHFSA-N;

Icalcaprant^[1] (developmental code name CVL-354) is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders.^[2]^[3] It is taken by mouth.^[2]

It acts as a selective antagonist of the κ-opioid receptor.^[2]^[3] The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor.^[3]

It was originated by Pfizer and is under development by Cerevel Therapeutics (a subsidiary of AbbVie).^[2]^[4] As of September 2022, icalcaprant is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.^[2]